Wenzhou Medical University

high-precision BE for inherited blindness; prenatal editing.

Country: China

Coverage

	CN	EU	US
genome-engineering	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Affiliation	Wenzhou Medical University	wzkj.wenzhou.gov.cn
Research focus	Gene editing for inherited blindness, including adenine base editor repair of RHO gene mutations and CRB1-related retinal degeneration	kjc.wmu.edu.cn · pmc.ncbi.nlm.nih.gov · wzkj.wenzhou.gov.cn
Facility	Eye Hospital of Wenzhou Medical University; State Key Laboratory of Ophthalmology, Optometry and Visual Science; National Clinical Research Center for Ocular Diseases; National Engineering Research Center for Ophthalmology and Optometry; Key Laboratory of Clinical Research and Evaluation of Medical Devices and Drugs for Ophthalmology Diseases; Provincial Key Laboratory of Ophthalmic Drug Innovation and Medical Device R&D	en.wmu.edu.cn · en.wzeye.cn · kjc.wmu.edu.cn
Grant	Wenzhou Municipal Science and Technology Project (Project H20210011, 100,000 RMB); National Key R&D Program grants (23.32 million and 21 million RMB)	kjc.wmu.edu.cn · wzkj.wenzhou.gov.cn
Publications	Over 300 SCI papers in relevant areas, including publications in Cell Metabolism and Ophthalmology journals	journals.lww.com · kjc.wmu.edu.cn · wzkj.wenzhou.gov.cn
Principal staff	Gu Feng (Project Lead for RHO gene repair); Lu Fan (Laboratory Director); Li Xiaokun (Academic Committee Chair); Xia Erning; Li Xingyi; Xu Liangde	kjc.wmu.edu.cn · pubmed.ncbi.nlm.nih.gov · wzkj.wenzhou.gov.cn
Headcount	60 fixed members in the Provincial Key Laboratory of Ophthalmic Drug Innovation and Medical Device R&D	kjc.wmu.edu.cn

Independent sources: en.wmu.edu.cn · en.wzeye.cn · journals.lww.com · kjc.wmu.edu.cn · pmc.ncbi.nlm.nih.gov · pubmed.ncbi.nlm.nih.gov · wzkj.wenzhou.gov.cn

Technologies

Name	Cluster	Risk
Base editing	genome-engineering	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.